TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27167367

Group type: EXPERIMENTAL
Intervention: Group C (axillary ultrasound, laser, and postisometric facilitation technique)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group B (axillary ultrasound and laser applied to the axillary region)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group A (standard care with traditional physical therapy)
Number of subjects: 45
Study: 25050903

Group type: EXPERIMENTAL
Intervention: Single session of ultrasound-guided laser ablation therapy (LAT) using a 1064nm Nd-YAG laser source at 3 W output power.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Follow-up with no treatment (Control group).
Number of subjects: 200
Study: 22228439

Group type: EXPERIMENTAL
Intervention: Palatal implants
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 20116959

Group type: EXPERIMENTAL
Intervention: Craving Beliefs Questionnaire (CBQ)
Number of subjects: 214
Study: 18705707

Group type: EXPERIMENTAL
Intervention: Above-median fluid intake (24 ml/kg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Below-median fluid intake (16 ml/kg/day)
Number of subjects: 63
Study: 16051399

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730, 1x10(8) cfu/tablet twice a day for 6 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11824856

Group type: EXPERIMENTAL
Intervention: L-arginine 100 mg/kg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: L-arginine 250 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: L-arginine 250 mg/kg with L-NMMA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: L-NMMA before L-arginine infusion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Subsequent infusion of L-arginine after L-NMMA
Number of subjects: 29
Study: 10073501

Group type: EXPERIMENTAL
Intervention: Hyaluronan loading test with intravenous injection of 7.5 mg HYA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls (n=15)
Number of subjects: 21
Study: 7722709

Group type: EXPERIMENTAL
Intervention: High protein-energy supplement (Atole)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-energy, no-protein supplement (Fresco)
Number of subjects: 0
Study: 2183665

Group type: EXPERIMENTAL
Intervention: Ibuprofen, 800 mg three times daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piroxicam, 20 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sulindac, 200 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibuprofen, piroxicam, and sulindac (combined)
Number of subjects: 12
Study: 6276883

Group type: EXPERIMENTAL
Intervention: Vitamin D analogues (1 alpha hydroxyvitamin D3 or dihydrotachysterol, n = 12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Calcium therapy (Control group, n = 9)
Number of subjects: 21
Study: 31923471

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI) 40 IU daily for 24 weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI)
Number of subjects: 210
Study: 30799103

Group type: EXPERIMENTAL
Intervention: Once-a-day milk feeding with live yeast culture and mannan-rich fraction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Twice-a-day milk feeding with live yeast culture and mannan-rich fraction
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Once-a-day milk feeding without yeast
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Twice-a-day milk feeding without yeast
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calves fed yeast
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calves fed milk once a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calves fed milk twice a day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Calves fed milk once or twice a day
Number of subjects: 48
Study: 28497755

Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 45
Study: 26735507

Group type: EXPERIMENTAL
Intervention: Resourcefulness Training (RT)
Number of subjects: 138
Study: 25173538

Group type: EXPERIMENTAL
Intervention: Intensified cardiovascular risk multi‐intervention (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (n = 50)
Number of subjects: 100
Study: 22893628

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks
Number of subjects: 2046

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks
Number of subjects: 2046

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Number of subjects: 2046

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg
Number of subjects: 2046
Study: 19458560

Group type: EXPERIMENTAL
Intervention: Microdose transdermal E2 (0.014 mg/d)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Low-dose transdermal E2 plus levonorgestrel (0.023 mg/d E2/0.0075 mg/d levonorgestrel)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 17766600

Group type: EXPERIMENTAL
Intervention: Foley catheter with extraamniotic saline infusion
Number of subjects: 188

Group type: COMPARATOR
Intervention: Foley catheter alone
Number of subjects: 188
Study: 15099990

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) (25 mg sulfadoxine and 1.25 mg pyrimethamine/kg)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Chloroquine (CQ) (25 mg/kg)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 117
Study: 11207019

Group type: EXPERIMENTAL
Intervention: Intensive patient education (80 patients)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional patient education (70 patients)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Peak expiratory flow (PEF)-based self-management
Number of subjects: 162
Study: 9784662

Group type: EXPERIMENTAL
Intervention: Prestorage-filtered apheresis platelets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bedside-filtered platelets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (prestorage-filtered and bedside-filtered)
Number of subjects: 0
Study: 8018453

Group type: EXPERIMENTAL
Intervention: Anpirtoline (60 mg orally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tramadol (150 mg orally)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg orally)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2658483

Group type: EXPERIMENTAL
Intervention: Anti-smoking intervention and extensive contact with study personnel
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 700
Study: 1103074

Group type: EXPERIMENTAL
Intervention: Dyphylline 15 mg/kg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31602966

Group type: EXPERIMENTAL
Intervention: 60 mg extended-release oral trospium 1 h before induction of anesthesia
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 31200321

Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg every 3 weeks for a total of 18 doses (∼1 year)
Number of subjects: 1019

Group type: COMPARATOR
Intervention: placebo every 3 weeks for a total of 18 doses (∼1 year)
Number of subjects: 1019

Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 1019
Study: 27892704

Group type: EXPERIMENTAL
Intervention: 16-week aerobic exercise programme, 3 times per week (2 supervised sessions and 1 unsupervised session)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No intervention (control group), n=6
Number of subjects: 11
Study: 25858012

Group type: EXPERIMENTAL
Intervention: Usual care plus the education programme
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 23
Study: 22840286

Group type: EXPERIMENTAL
Intervention: Olanzapine (4 weeks treatment)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pre-treatment (no medication)
Number of subjects: 22
Study: 21294631

Group type: EXPERIMENTAL
Intervention: Forearm immersion (FI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ice water perfused cooling vest (CV)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Passive cooling (P)
Number of subjects: 25
Study: 19321562

Group type: EXPERIMENTAL
Intervention: HF diet with saturated fat (SE)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HF diet with monounsaturated fat (UE)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary condition with saturated fat (SS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary condition with monounsaturated fat (US)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SE and SS treatments
Number of subjects: 8
Study: 17083288

Group type: EXPERIMENTAL
Intervention: External reinforcement during motion direction discrimination task
Number of subjects: 2

Group type: COMPARATOR
Intervention: No external reinforcement during motion direction discrimination task
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: External reinforcement during orientation-discrimination sessions
Number of subjects: 2

Group type: COMPARATOR
Intervention: No external reinforcement during orientation-discrimination sessions
Number of subjects: 2
Study: 15103466

Group type: EXPERIMENTAL
Intervention: Ileostomy
Number of subjects: 214

Group type: COMPARATOR
Intervention: No ileostomy
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Overall small bowel obstruction
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Malignant obstruction
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Obstruction within 6 weeks of surgery
Number of subjects: 214
Study: 11592726

Group type: EXPERIMENTAL
Intervention: CLA supplementation (3.9 g/d for 64 d)
Number of subjects: 6
Study: 9638695

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma added to grafts
Number of subjects: 0

Group type: COMPARATOR
Intervention: No platelet-rich plasma added to grafts
Number of subjects: 0
Study: 7988302

Group type: COMPARATOR
Intervention: Conventional treatment given by community health centers
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intensified dietary and exercise education given by a university outpatient clinic
Number of subjects: 78
Study: 3056131

Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29855271

Group type: EXPERIMENTAL
Intervention: Maternal nutritional supplement (140 kcal/serving, 7.9 g protein, multivitamin/minerals, with or without probiotics)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Combined supplemented groups (with or without probiotics)
Number of subjects: 208

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 208
Study: 27765800

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 μg/d for 12 weeks)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Vitamin B12
Number of subjects: 324
Study: 26479484

Group type: EXPERIMENTAL
Intervention: Lubo aus dem All! - Vorschulalter (intervention group)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional kindergarten activities (control group)
Number of subjects: 221
Study: 24148829

Group type: EXPERIMENTAL
Intervention: Providing calculated 10-year cardiovascular risk (Framingham risk score)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (received clinical vignettes with all information on risk factors)
Number of subjects: 0
Study: 21499703

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 461

Group type: COMPARATOR
Intervention: Gefarnate 50 mg twice daily
Number of subjects: 461
Study: 18327581

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 227

Group type: COMPARATOR
Intervention: Assessment-only (Control)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Local recurrences
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Distant recurrence
Number of subjects: 227
Study: 12747343

Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: 0.10% ropivacaine
Number of subjects: 105
Study: 10584983

Group type: EXPERIMENTAL
Intervention: Controlled ovarian hyperstimulation (COH)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (baseline hormonal profile)
Number of subjects: 15
Study: 8751017

Group type: EXPERIMENTAL
Intervention: Controlled release (CR) diltiazem, given twice a day (b.i.d.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Plain diltiazem, given four times a day (q.i.d.)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both CR and plain diltiazem
Number of subjects: 41
Study: 2225497

Group type: EXPERIMENTAL
Intervention: Calcium alginate haemostatic swabs
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal gauze swabs
Number of subjects: 72
Study: 367575

Group type: EXPERIMENTAL
Intervention: Methyl CCNU, 5-FU and Vincristine (MOF A)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Methyl CCNU, 5-FU and Vincristine (MOF B)
Number of subjects: 67
Study: 31672329

Group type: EXPERIMENTAL
Intervention: BCAAem supplementation
Number of subjects: 155

Group type: COMPARATOR
Intervention: Diet advice (Control)
Number of subjects: 155
Study: 30857647

Group type: EXPERIMENTAL
Intervention: Veverimer 6 g/day
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 27661788

Group type: EXPERIMENTAL
Intervention: Patient-centered methadone treatment (PCM; n = 149)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU; n = 151)
Number of subjects: 300
Study: 25385260

Group type: EXPERIMENTAL
Intervention: Decernotinib 25 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Decernotinib 50 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Decernotinib 100 mg
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Decernotinib 150 mg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 24093324

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aspirin and placebo
Number of subjects: 80
Study: 21854643

Group type: EXPERIMENTAL
Intervention: Structured medication assessment including withdrawal of fall-risk increasing drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 19383161

Group type: EXPERIMENTAL
Intervention: Accurate++ probe
Number of subjects: 20

Group type: COMPARATOR
Intervention: Coach probe
Number of subjects: 20
Study: 17279301

Group type: EXPERIMENTAL
Intervention: 5‐mmx5‐mm pieces of latex‐free rubber
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 12‐mmx1.5‐mm metallic bowel clips
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall markers (both types)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cecal intubation
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Insertion and withdrawal times
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Detection rates by endoscopists
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Markers placed at flexures
Number of subjects: 44
Study: 15491246

Group type: EXPERIMENTAL
Intervention: nefazodone + GC
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: nefazodone + CBT
Number of subjects: 242

Group type: COMPARATOR
Intervention: placebo + CBT
Number of subjects: 242

Group type: COMPARATOR
Intervention: placebo + GC
Number of subjects: 242
Study: 11830755

Group type: EXPERIMENTAL
Intervention: Eptastigmine
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 9621140

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 3 months followed by itraconazole 200 mg once weekly for 3 months (ITR-ITR group)
Number of subjects: 1608

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 3 months followed by oral placebo once weekly for 3 months (ITR-PLAC group)
Number of subjects: 1608

Group type: COMPARATOR
Intervention: Miconazole cream twice daily for 6 months (MIC-MIC group)
Number of subjects: 1608
Study: 8173149

Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg q12h
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg qd
Number of subjects: 607

Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 units q8h
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Enoxaparin groups (30 mg and 40 mg)
Number of subjects: 607
Study: 30706733

Group type: EXPERIMENTAL
Intervention: Intervene video
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1243
Study: 29116826

Group type: EXPERIMENTAL
Intervention: TENS with adjustment of pulse amplitude
Number of subjects: 21

Group type: COMPARATOR
Intervention: TENS without adjustment of pulse amplitude
Number of subjects: 21
Study: 27431049

Group type: EXPERIMENTAL
Intervention: Buprenorphine linkage (induction, stabilization, bridge prescription, and facilitated referral to outpatient treatment)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Detoxification (5-day inpatient buprenorphine taper)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Buprenorphine linkage
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Non-buprenorphine days
Number of subjects: 113
Study: 24933451

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT), 7-10 weekly modules guided by online therapists
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 100
Study: 22870676

Group type: EXPERIMENTAL
Intervention: Pizhen treatment
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intra-articular injection with sodium hyaluronate (Control)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Comparison between Pizhen and Control
Number of subjects: 85
Study: 20207411

Group type: EXPERIMENTAL
Intervention: Participatory intervention with women's groups
Number of subjects: 19030

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19030
Study: 19465145

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) plus behavior therapy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Behavior therapy only (Control)
Number of subjects: 109
Study: 16553955

Group type: EXPERIMENTAL
Intervention: Immediate blood test ordering (Group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watchful waiting policy (Group 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postponement of testing with quality improvement strategy (Group 3)
Number of subjects: 0
Study: 15223858

Group type: EXPERIMENTAL
Intervention: Doubling the dose (DD) of inhaled corticosteroid
Number of subjects: 290

Group type: COMPARATOR
Intervention: Maintenance dose (MD) of inhaled corticosteroid
Number of subjects: 290
Study: 11205650

Group type: EXPERIMENTAL
Intervention: Standard education plus computer‐assisted instruction (CAI)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 86
Study: 11248878

Group type: EXPERIMENTAL
Intervention: Interesterified fat blend
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-interesterified fat blend
Number of subjects: 60
Study: 8279255

Group type: EXPERIMENTAL
Intervention: 2-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 4-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 12-hour fasting interval after ingestion of apple juice (10 ml/kg b.w.)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (2-hour fasting interval)
Number of subjects: 105
Study: 2886997

Group type: EXPERIMENTAL
Intervention: Fluperlapine (NB‐106‐689)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 26
Study: 31648815

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 3 g per day for 5 days before and 21 days after surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 29114733

Group type: EXPERIMENTAL
Intervention: Sodium oxybate (3.0 to 9.0 g per night for 6 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27064832

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 73

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 73
Study: 24953067

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7.5% povidone‐iodine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alcohol‐based hand rub
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plain soap and water
Number of subjects: 80
Study: 23185261

Group type: EXPERIMENTAL
Intervention: Fosamax (Alendronate Sodium)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Immunosuppressive agents
Number of subjects: 76
Study: 21086869

Group type: EXPERIMENTAL
Intervention: HeartCode BLS with voice assisted manikin (VAM)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Standard instructor-led (IL) course with regular manikins
Number of subjects: 603
Study: 18698047

Group type: EXPERIMENTAL
Intervention: gp100(209-2M) immunization
Number of subjects: 0
Study: 15774213

Group type: EXPERIMENTAL
Intervention: Gabapentin 200 mg/d
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 12695266

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin(s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ximelagatran (direct thrombin inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nematode anticoagulant peptide c2 (tissue factor VIIa inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium N-[8(2-hydroxylbenzoyl)amino] caprylate (SNAC)/heparin (heparin derivative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Danaparoid sodium (heparinoid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fondaparinux (selective factor Xa inhibitor)
Number of subjects: 0
Study: 10323374

Group type: EXPERIMENTAL
Intervention: 100 mg DHEA for 3 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 39